Molecular Pathologies of and Enzyme Replacement Therapies for Lysosomal Diseases

Author(s): Hitoshi Sakuraba, Makoto Sawada, Fumiko Matsuzawa, Sei-ichi Aikawa, Yasunori Chiba, Yoshifumi Jigami, Kohji Itoh

Journal Name: CNS & Neurological Disorders - Drug Targets
Formerly Current Drug Targets - CNS & Neurological Disorders

Volume 5 , Issue 4 , 2006

Become EABM
Become Reviewer
Call for Editor


Lysosomal diseases comprise a group of inherited disorders resulting from defects of lysosomal enzymes and their cofactors, and in many of them the nervous system is affected. Recently, enzyme replacement therapy with recombinant lysosomal enzymes has been clinically available for several lysosomal diseases. Such enzyme replacement therapies can improve non-neurological disorders but is not effective for neurological ones. In this review, we discuss the molecular pathologies of lysosomal diseases from the protein structural aspect, current enzyme replacement therapies, and attempts to develop enzyme replacement therapies effective for lysosomal diseases associated with neurological disorders, i.e., production of enzymes, brain-specific delivery and incorporation of lysosomal enzymes into cells.

Keywords: Lysosomal enzyme, lysosomal disease, Tay-Sachs disease, Sandhoff disease, Fabry disease, protein structure, enzyme replacement therapy, drug delivery

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2006
Page: [401 - 413]
Pages: 13
DOI: 10.2174/187152706777950738
Price: $65

Article Metrics

PDF: 15